These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 9285690)

  • 1. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.
    Ueno NT; Yu D; Hung MC
    Oncogene; 1997 Aug; 15(8):953-60. PubMed ID: 9285690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.
    Ueno NT; Bartholomeusz C; Herrmann JL; Estrov Z; Shao R; Andreeff M; Price J; Paul RW; Anklesaria P; Yu D; Hung MC
    Clin Cancer Res; 2000 Jan; 6(1):250-9. PubMed ID: 10656456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
    Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
    Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Down regulation of HER2/neu expression by adenovirus E1A and its anti-tumor activity].
    Lu H; Qin H; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2000 Sep; 22(5):370-3. PubMed ID: 11778270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer.
    Liao Y; Zou YY; Xia WY; Hung MC
    Cancer Gene Ther; 2004 Sep; 11(9):594-602. PubMed ID: 15272313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of intratracheal lung cancer development by systemic delivery of E1A.
    Chang JY; Xia W; Shao R; Hung MC
    Oncogene; 1996 Oct; 13(7):1405-12. PubMed ID: 8875978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene.
    Ueno NT; Bartholomeusz C; Xia W; Anklesaria P; Bruckheimer EM; Mebel E; Paul R; Li S; Yo GH; Huang L; Hung MC
    Cancer Res; 2002 Nov; 62(22):6712-6. PubMed ID: 12438271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms.
    Yu D; Liu B; Tan M; Li J; Wang SS; Hung MC
    Oncogene; 1996 Sep; 13(6):1359-65. PubMed ID: 8808711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu.
    Yu D; Matin A; Xia W; Sorgi F; Huang L; Hung MC
    Oncogene; 1995 Oct; 11(7):1383-8. PubMed ID: 7478560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model.
    Zhang Y; Yu D; Xia W; Hung MC
    Oncogene; 1995 May; 10(10):1947-54. PubMed ID: 7761095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
    Zhang L; Lau YK; Xia W; Hortobagyi GN; Hung MC
    Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
    Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs.
    Zhou Z; Jia SF; Hung MC; Kleinerman ES
    Cancer Res; 2001 Apr; 61(8):3394-8. PubMed ID: 11309298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer.
    Yoo GH; Hung MC; Lopez-Berestein G; LaFollette S; Ensley JF; Carey M; Batson E; Reynolds TC; Murray JL
    Clin Cancer Res; 2001 May; 7(5):1237-45. PubMed ID: 11350889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
    Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
    Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
    McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
    J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of E1A gene on in vitro growth inhibition and radiochemosensitivity of lymph node metastasis cells of human head and neck squamous cell carcinoma].
    Wang XL; Qian XL; Zhao QZ; Xu ZG; Tang PZ
    Ai Zheng; 2003 Nov; 22(11):1140-6. PubMed ID: 14613640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
    Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ
    Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2.
    Wright M; Grim J; Deshane J; Kim M; Strong TV; Siegal GP; Curiel DT
    Gene Ther; 1997 Apr; 4(4):317-22. PubMed ID: 9176517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Technology evaluation: tgDCC-E1A, targeted genetics/MD Anderson.
    Wagner JA
    Curr Opin Mol Ther; 1999 Apr; 1(2):266-70. PubMed ID: 11715950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.